IDIS has been 100% owned by CLINIGEN GROUP since April 2015.

At what enterprise value was IDIS acquired in 2015?

During the acquisition of IDIS by CLINIGEN GROUP in 2015, the transaction's Enterprise Value is estimated to be in the range of £100–350M.

What was the EV/EBITDA of IDIS when it was acquired by CLINIGEN GROUP?

The estimated EV/EBITDA multiple for IDIS is in the range of 10x - 18x.

What was the EV/Revenue multiple of IDIS when it was acquired by CLINIGEN GROUP?

The estimated EV/Revenue multiple for IDIS is in the range of 1x - 3x.

When was IDIS acquired by CLINIGEN GROUP?

IDIS was acquired by CLINIGEN GROUP in 2015.

What was the revenue of IDIS at the time of the deal?

The revenue of IDIS at the time of the deal is estimated to be in the range of £100–200M.

What was the EBITDA of IDIS during the acquisition?

IDIS's EBITDA is estimated to be in the range of £5–25M.

How is the data for the IDIS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the IDIS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.unquote.com/uk/official-record/85857/cbpe-scores-22x-return-on-idis-sale

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaIDIS

04/2015

IDIS acquired by CLINIGEN GROUP

UNITED KINGDOM Healthcare Services EV £100–350M

Context

Clinigen Group acquired IDIS from private equity firm CBPE Capital. This acquisition brings together the two leading players in the ethical unlicensed medicines market. For CBPE, this exit represents a phenomenal success story: after backing the management buyout in 2005 and holding the asset for a decade, they achieved a 22x return on their original investment. The industrial logic for Clinigen is to consolidate the fragmented $5 billion unlicensed medicines market, combining IDIS's regulatory expertise and broad geographic footprint with Clinigen's existing infrastructure to serve healthcare professionals and pharma clients more effectively worldwide.

IDIS, which reported an EBITDA margin of [members only] in 2015, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a level close to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1987 and headquartered in Weybridge (with a US base in Princeton), IDIS is a specialized provider of "Managed Access Programs" (MAPs). The company helps pharmaceutical companies provide ethical access to unlicensed medicines for patients with unmet medical needs (e.g., providing a cancer drug to a patient in a country where it is not yet approved). It navigates the complex regulatory landscape to supply medication in nearly 100 countries.

Ent. Value

£100–350M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2015

2014

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	CRO / Clinical Trials
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	CRO / Clinical Trials
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Health Tech
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services
11/2020	KERSIA	SOPURA	BELGIUM	Sterilization & Hygiene
10/2020	IK PARTNERS	KERSIA	FRANCE	Sterilization & Hygiene
05/2020	CLAYTON, DUBILIER & RICE (CD&R)	HUNTSWORTH	UNITED KINGDOM	Healthcare Services
03/2020	LDC	AGENTIS HEALTH GROUP	UNITED KINGDOM	Healthcare Services
01/2018	SPECTRIS	CONCEPT LIFE SCIENCES	UNITED KINGDOM	CRO / Clinical Trials
04/2016	CHARLES RIVER LABORATORIES	WIL RESEARCH	UNITED STATES	CRO / Clinical Trials

REFERENCES

Valuation range: EV £100–350M

Revenue range: £100–200M

EBITDA range: £5–25M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IDIS by CLINIGEN GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.